Skip to content
akaturk Academic measurement
Sign in Sign up

OpenAlex topic

Adrenal Hormones and Disorders

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 2,552 works 27 author topics

Works

2,552 works

  1. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes 2020
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown. METHODS: . All the patients were…

  2. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    No abstract yet.

  3. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    No abstract yet.

  4. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    No abstract yet.

  5. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    No abstract yet.

  6. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    No abstract yet.

  7. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. 2024
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety…

  8. Clinical picture and treatment of 2212 patients with common variable immunodeficiency 2014
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.7%

    No abstract yet.

  9. A 12 month phase 3 study of pasireotide in Cushing s disease Colao A Petersenn S Newell Price J Findling JW Gu F Maldonado M Schoenherr U Mills D Salgado LR Biller BM Pasireotide B2305 Study Group 2012
    YÖKSİS OpenAlex top 1% OpenAlex 99.9%

    BACKGROUND: Cushing's disease is associated with high morbidity and mortality. Pasireotide, a potential therapy, has a unique, broad somatostatin-receptor-binding profile, with high binding affinity for somatostatin-receptor subtype 5. METHODS: In this double-blind, phase 3 study, we randomly assigned 162 adults with…

  10. Corticotropin Tests for Hypothalamic Pituitary Adrenal Insufficiency A Metaanalysis 2008
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 10% OpenAlex 98.9%

    CONTEXT: The diagnostic value of tests for detecting hypothalamic-pituitary adrenal insufficiency (HPAI) is controversial. OBJECTIVE: Our objective was to compare standard-dose and low-dose corticotropin tests for diagnosing HPAI. DATA SOURCES: We searched the PubMed database from 1966-2006 for studies reporting diagn…

  11. Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study 2018
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.5%

    BACKGROUND: Immunodysregulation polyendocrinopathy enteropathy x-linked (IPEX) syndrome is a monogenic autoimmune disease caused by FOXP3 mutations. Because it is a rare disease, the natural history and response to treatments, including allogeneic hematopoietic stem cell transplantation (HSCT) and immunosuppression (I…

  12. The ratio of second and fourth digit lengths and congenital adrenal hyperplasia due to 21 hydroxylase deficiency 2002
    YÖKSİS SJR Q1 JCR Q2 OpenAlex top 10% OpenAlex 95.2%

    No abstract yet.

Academicians

27 academicians